Vertex Pharmaceuticals Q1 2026 Revenue $2.99B Beats Market Expectations
Vertex Pharmaceuticals (VRTX) reported Q1 2026 revenue of $2.99 billion, up 8% year-over-year. GAAP net income reached $1.0 billion with significant improvement, while the company maintained full-year revenue guidance of $12.95–$13.1 billion.
- Vertex reported Q1 2026 revenue of $2.99 billion, beating expectations with 8% YoY growth
- The stock fell 1.93% despite strong earnings and profit growth, as the company maintained its annual revenue guidance unchanged
Vertex Pharmaceuticals (VRTX) reported Q1 2026 revenue of $2.99 billion, exceeding market consensus, according to an SEC 8-K filing.
📊 Stock Price at Time of Report (May 6, 2026, 03:00 KST)
$421.57 ▼ -1.93%
Approximately ₩619,286 (Exchange rate: 1469)
Quarterly Results at a Glance
Vertex's Q1 revenue grew 8% year-over-year, driven by steady cystic fibrosis (CF) therapeutic sales. Growth was further supported by new product launches including sickle cell disease and acute pain treatments.
- Revenue: $2.99 billion, +8% YoY
- GAAP Net Income: $1.0 billion vs. $646 million in prior year
- Non-GAAP Adjusted Net Income: $1.1 billion, up $93 million YoY
- U.S. Revenue: $1.78 billion, +7% YoY
- International Revenue: $1.21 billion, +9% YoY
- Cash and Marketable Securities: $13.0 billion (as of March 31, 2026)
Full-Year Guidance
Vertex maintained its 2026 full-year revenue guidance at $12.95–$13.1 billion, with non-CF product revenues expected to exceed $500 million. CEO Reshma Kewalramani noted that growth from sickle cell disease, beta-thalassemia, and acute pain treatments drove over 25% of total growth, and the company is expanding into the renal disease space. Management expects tariff impacts to be minimal in 2026.
Market Reaction
Vertex shares declined following the earnings announcement. As of May 6, 2026, 03:00 KST, the stock traded at $421.57, down 1.93% from the prior close. Industry sources including StockStory and Yahoo Finance reported that both revenue and earnings exceeded consensus estimates. The maintenance of flat full-year guidance was cited as a key factor in the share price decline.
Key Pipeline Developments
Vertex completed a Biologics License Application (BLA) submission for povetacicept, a renal disease therapeutic candidate, requesting priority review for IgA nephropathy. The company also initiated clinical trials in primary membranous nephropathy and myasthenia gravis. The existing CF therapy ALYFTREK has now gained approvals across 8 regions including the U.S., UK, and EU. CASGEVY, the sickle cell and beta-thalassemia treatment, completed a U.S. BLA submission for pediatric patients ages 5 to under 12.
This article was auto-generated from the SEC 8-K filing and external news reports to provide timely dissemination of key financial data. Investors are advised to review official company disclosures before making trading decisions. Stock prices are as of report publication and may differ from current levels.
VRTXFrequently Asked Questions
What was Vertex's Q1 revenue and did it exceed expectations?
Vertex reported Q1 2026 revenue of $2.99 billion, representing 8% year-over-year growth. According to industry reports, the company beat consensus expectations.
What is the difference between GAAP and non-GAAP net income?
GAAP (Generally Accepted Accounting Principles) includes all items such as stock-based compensation and asset impairments, reflecting official accounting standards. Non-GAAP (adjusted) excludes one-time items to show underlying operational performance. This quarter, GAAP net income was $1.0 billion versus non-GAAP net income of $1.1 billion.
Why did the stock decline despite beating earnings?
While both revenue and earnings exceeded market consensus, Vertex maintained its full-year revenue guidance without an upward revision. Market participants had anticipated raised guidance, and the absence of it prompted the modest 1.93% share price decline.
What is povetacicept and where does it stand?
Povetacicept is Vertex's investigational renal disease therapeutic targeting IgA nephropathy, an immune-mediated kidney disease. The company completed a Biologics License Application (BLA) with the FDA and requested priority review, positioning renal disease as a key growth pillar alongside its existing CF franchise.
IonQ Reports Q1 2026 Earnings on 6th: 556% Revenue Growth, $1.8B Skywater Acquisition Included
IONQ
SKYT
QBTS+4
Morgan Stanley Raises AMD Price Target to $360 from $255; Meta 6GW Deployment and Oracle Orders Confirmed
AMD
NVDA
INTC+7
Palantir Stock Falls 6% Despite 85% Growth Beat—Perfect Results Miss Perfect Expectations
PLTR
SNOW
DDOG+4Wall Street's Defining Moments
See more
Smart Money Briefing
Weekly summaries of Wall Street guru moves and crypto whale activity.
